<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556228</url>
  </required_header>
  <id_info>
    <org_study_id>VMO-01C</org_study_id>
    <nct_id>NCT03556228</nct_id>
  </id_info>
  <brief_title>Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma</brief_title>
  <official_title>An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VM Oncology, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VM Oncology, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult&#xD;
      subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to&#xD;
      available therapies and for which no standard or available curative therapy exists&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase I, FTIH, multiple-dose, dose-escalation and cohort expansion&#xD;
      multi-center study conducted in three parts to identify a safe and pharmacologically active&#xD;
      dose and regimen for VMD-928 monotherapy, which can be implemented in Phase 2 studies (the&#xD;
      RP2D). The regimen will be identified using an adaptive design, multiple-ascending dose study&#xD;
      in cancer patients. To conserve patients in the lower dose cohorts, dose escalation will&#xD;
      begin with an accelerated titration scheme. A second part of the study will assess antitumor&#xD;
      activity at the RP2D. The third part of the study will collect tumor samples before and after&#xD;
      treatment to assess biological activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1, Dose Escalation: Identify the RP2D (complete);&#xD;
Parts 2-4, Cohort Expansion with RP2D (ongoing);</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of treatment-emergent AEs</measure>
    <time_frame>Within two months of the first VMD-928 dose for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of VMD-928.</measure>
    <time_frame>Two to three months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of VMD-928.</measure>
    <time_frame>Two to three months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Dose Limiting Toxicities.</measure>
    <time_frame>Within two months of the first VMD-928 dose for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic response as defined by the Brief Pain Inventory (BPI).</measure>
    <time_frame>Within two months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-TrkA protein expression.</measure>
    <time_frame>Pre-dose and within two months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between clinical antitumor and AUC.</measure>
    <time_frame>Six to eight months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between clinical antitumor and p-TrkA inhibition.</measure>
    <time_frame>Six to eight months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between analgesic response and p-TrkA inhibition.</measure>
    <time_frame>Six to eight months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between analgesic response and AUC.</measure>
    <time_frame>Six to eight months after starting treatment for each patient [Estimated]</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Thymic Carcinoma and Thymoma</condition>
  <condition>Mesothelioma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of Lung</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Adenoid Cystic Carcinoma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>VMD-928 300 mg Tablet or 100 mg Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VMD-928 300 mg Tablets or 100 mg Capsules</intervention_name>
    <description>Taken orally once daily</description>
    <arm_group_label>VMD-928 300 mg Tablet or 100 mg Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part-1 Dose Escalation [Key Inclusion]:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of solid tumor malignancy or&#xD;
             lymphoma that is not responsive to standard therapies, are unfit for standard&#xD;
             chemotherapy or for which there is no approved or curative therapy.&#xD;
&#xD;
          -  ECOG score of 0 or 1.&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  Adequate organ system function.&#xD;
&#xD;
        Parts 2-4 Cohort Expansion Only [Key Inclusion]:&#xD;
&#xD;
          -  Part 1 inclusion criteria.&#xD;
&#xD;
          -  Subjects must either have available archival tumor tissue samples, or consent to tumor&#xD;
             tissue sampling prior to the first dose, that is sufficient for IHC analysis of TrkA&#xD;
             expression, AND have a tumor or tumor type in one of the following categories:&#xD;
&#xD;
             (i). Tumors showing a response or stable disease after at least 2 cycles of VMD-928&#xD;
             during Part 1;&#xD;
&#xD;
        (ii). Tumor types associated with high TrkA protein overexpression, i.e.:&#xD;
&#xD;
          -  Thymic carcinoma and thymoma&#xD;
&#xD;
          -  Mesothelioma&#xD;
&#xD;
          -  Head and neck squamous cell carcinoma (HNSCC)&#xD;
&#xD;
          -  Ovarian cancer (especially serous)&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Squamous cell carcinoma of lung (squamous NSCLC)&#xD;
&#xD;
          -  Esophageal cancer&#xD;
&#xD;
          -  Adenoid cystic carcinoma&#xD;
&#xD;
          -  Prostate cancer&#xD;
&#xD;
          -  Cervical cancer&#xD;
&#xD;
          -  Gastric cancer&#xD;
&#xD;
          -  Melanoma&#xD;
&#xD;
          -  Acute myeloid leukemia&#xD;
&#xD;
          -  Pancreatic carcinoma&#xD;
&#xD;
          -  Non-Hodgkins' lymphoma&#xD;
&#xD;
        (iii). Tumors with documented NTRK1 gene fusions or amplifications, or TrkA protein&#xD;
        overexpression, or a tumor which has progressed due to NTRK1 mutation after treatment of a&#xD;
        pan-Trk inhibitor (e.g. larotrectinib or entrectinib)&#xD;
&#xD;
        Part 3 Pharmacodynamic Activity only (Eligible subjects in Part 2 may enroll in Part 3):&#xD;
&#xD;
          -  Part-2 inclusion criteria.&#xD;
&#xD;
          -  Tumor with readily accessible lesion that is amenable to biopsy and consent to pre-and&#xD;
             post-dose biopsy.&#xD;
&#xD;
        Part 4 Exploratory Comparative PK of Tablet vs. Capsule Formulations only (Eligible&#xD;
        subjects in Part 2 or 3 will be encouraged to enroll in Part 4)&#xD;
&#xD;
        Key Exclusion Criteria (Parts 1-4):&#xD;
&#xD;
          1. Received chemotherapy having delayed toxicity within the last 21 days (six weeks for&#xD;
             prior nitrosourea or mitomycin C).&#xD;
&#xD;
          2. Received anticancer therapy with radiation, immunotherapy, a biologic, surgery and/or&#xD;
             tumor embolization within the past 2 weeks.&#xD;
&#xD;
          3. Received an investigational anti-cancer drug within 21 days or 5 half-lives of the&#xD;
             investigational agent prior, whichever is longer, to the first dose of VMD-928.&#xD;
&#xD;
          4. Unresolved toxicity from previous anti-cancer therapy ≥ CTCAE Grade 1 (except alopecia&#xD;
             or anemia) unless agreed to by both the Investigator and Sponsor.&#xD;
&#xD;
          5. Negative result on TrkA-specific or pan-Trk IHC assay (Parts 2-4 only).&#xD;
&#xD;
          6. Known active infections including HIV disease.&#xD;
&#xD;
          7. Currently pregnant, nursing, or planning to become pregnant during the course of the&#xD;
             study.&#xD;
&#xD;
          8. QTcF interval ≥ 480 msec.&#xD;
&#xD;
          9. Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
             functional classification system.&#xD;
&#xD;
         10. Acute coronary syndromes (including unstable angina), coronary angioplasty, or&#xD;
             stenting within the past 24 weeks.&#xD;
&#xD;
         11. Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would&#xD;
             compromise the patient's safety or interfere with assessment of the drug.&#xD;
&#xD;
         12. Psychological, familial, sociological, geographical or other concurrent conditions&#xD;
             that would interfere with safety evaluation, limit the subject's ability to follow the&#xD;
             procedures in the protocol or otherwise jeopardize compliance with the protocol.&#xD;
             Subjects with uncontrolled major depression, bipolar disorder, or severe anxiety&#xD;
             disorder are excluded.&#xD;
&#xD;
             Key Exclusion Criteria (For Parts 1 and 4 only):&#xD;
&#xD;
         13. Any current medical condition that would alter the absorption, distribution,&#xD;
             metabolism or excretion of VMD-928 including but not limited to:&#xD;
&#xD;
               -  Severe uncontrolled nausea or vomiting&#xD;
&#xD;
               -  Severe uncontrolled diarrhea&#xD;
&#xD;
               -  With a history of short bowel syndrome&#xD;
&#xD;
               -  Clinically diagnosed malabsorption secondary to bowel resection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peg Fletcher, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>MedAssessment</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jay Wu, PhD</last_name>
    <phone>510-661-6770</phone>
    <phone_ext>101</phone_ext>
    <email>OM@VMOncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liz Gaynor; Cameron Wright</last_name>
    <phone>602-358-8344; 602-358-8341</phone>
    <email>egaynor@td2inc.com; cwright@td2inc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aruna V Parikh, M.B.B.S. CCRC</last_name>
      <phone>626-218-3419</phone>
      <phone_ext>83419</phone_ext>
      <email>arparikh@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Nikeeta Prajapati, RN, BSN</last_name>
      <phone>626-218-0029</phone>
      <phone_ext>80029</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Vincent Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System, Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Zitelli</last_name>
      <phone>973-971-6312</phone>
      <email>Leah.Cappadona@atlantichealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Rosemary Stefiniw</last_name>
      <phone>973-971-5990</phone>
      <email>Rosemary.Stefiniw@atlantichealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Alistar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell Medicine, Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Mavracick</last_name>
      <phone>646-962-8169</phone>
      <email>alm2074@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <phone>(646) 962-49‬69</phone>
      <email>gig4001@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Giaccone, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mianen Sun, PhD</last_name>
      <phone>832-540-0311</phone>
      <email>msun4@mdanderson.org</email>
    </contact>
    <contact_backup>
      <phone>713-563-1930</phone>
      <email>dshong@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>David S Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Jacklin</last_name>
      <phone>414-805-8839</phone>
      <email>mjacklin@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Holly Lemke</last_name>
      <phone>414-805-0261</phone>
      <email>hlemke@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sailaja Kamaraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TrkA</keyword>
  <keyword>NTRK1</keyword>
  <keyword>Thymic carcinoma and thymoma</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Squamous Cell Carcinoma of Lung (squamous NSCLC)</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Adenoid Cystic Carcinoma</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Non Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

